Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance
Emanuele Petruzzella, Roman Sirota, Irene Solazzo, et al.
Chemical Science (2018) Vol. 9, Iss. 18, pp. 4299-4307
Open Access | Times Cited: 131

Showing 1-25 of 131 citing articles:

A Multi‐action and Multi‐target RuII–PtIV Conjugate Combining Cancer‐Activated Chemotherapy and Photodynamic Therapy to Overcome Drug Resistant Cancers
Johannes Karges, Thirumal Yempala, Mickaël Tharaud, et al.
Angewandte Chemie International Edition (2020) Vol. 59, Iss. 18, pp. 7069-7075
Open Access | Times Cited: 199
Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications
Tiziana Tataranni, Cláudia Piccoli
Oxidative Medicine and Cellular Longevity (2019) Vol. 2019, pp. 1-14
Open Access | Times Cited: 193
Latest developments in metal complexes as anticancer agents
Renata Paprocka, Małgorzata Wiese-Szadkowska, Sabina Janciauskiene, et al.
Coordination Chemistry Reviews (2021) Vol. 452, pp. 214307-214307
Closed Access | Times Cited: 185
Metallodrugs in cancer nanomedicine
Quim Peña, Alec Wang, Orysia Zaremba, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 7, pp. 2544-2582
Closed Access | Times Cited: 144
What blocks more anticancer platinum complexes from experiment to clinic: Major problems and potential strategies from drug design perspectives
Kun Peng, Bing‐Bing Liang, Wenting Liu, et al.
Coordination Chemistry Reviews (2021) Vol. 449, pp. 214210-214210
Closed Access | Times Cited: 120
Multi-action Pt(IV) anticancer agents; do we understand how they work?
Dan Gibson
Journal of Inorganic Biochemistry (2018) Vol. 191, pp. 77-84
Closed Access | Times Cited: 146
Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment
Zhigang Wang, Zhiqin Deng, Guangyu Zhu
Dalton Transactions (2019) Vol. 48, Iss. 8, pp. 2536-2544
Closed Access | Times Cited: 128
Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies
Sepideh Mirzaei, Kiavash Hushmandi, Amirhossein Zabolian, et al.
Molecules (2021) Vol. 26, Iss. 8, pp. 2382-2382
Open Access | Times Cited: 97
Dual‐Targeting Dual‐Action Platinum(IV) Platform for Enhanced Anticancer Activity and Reduced Nephrotoxicity
Maria V. Babak, Zhi Yang, Bertrand Czarny, et al.
Angewandte Chemie International Edition (2019) Vol. 58, Iss. 24, pp. 8109-8114
Open Access | Times Cited: 94
Non-platinum complexes containing releasable biologically active ligands
Pavel Štarha, Zdeněk Trávnı́ček
Coordination Chemistry Reviews (2019) Vol. 395, pp. 130-145
Closed Access | Times Cited: 92
Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
Dan Gibson
Journal of Inorganic Biochemistry (2021) Vol. 217, pp. 111353-111353
Closed Access | Times Cited: 90
A view on multi-action Pt(IV) antitumor prodrugs
Mauro Ravera, Elisabetta Gabano, Michael J. McGlinchey, et al.
Inorganica Chimica Acta (2019) Vol. 492, pp. 32-47
Closed Access | Times Cited: 77
Interfering in apoptosis and DNA repair of cancer cells to conquer cisplatin resistance by platinum(iv) prodrugs
Shuren Zhang, Xuanmeng Zhong, Hao Yuan, et al.
Chemical Science (2020) Vol. 11, Iss. 15, pp. 3829-3835
Open Access | Times Cited: 72
In-vitro cytotoxicity and in-vivo antitumor activity of two platinum complexes with 1,3-dimethyl pentyl glycine ligand against breast cancer
Parisa Bazsefidpar, Ebrahim Eftekhar, Mohammad Zareian Jahromi, et al.
Journal of Inorganic Biochemistry (2023) Vol. 241, pp. 112144-112144
Closed Access | Times Cited: 24
The Self-Assembly of a Cyclometalated Palladium Photosensitizer into Protein-Stabilized Nanorods Triggers Drug Uptake In Vitro and In Vivo
Xue‐Quan Zhou, Ming Xiao, Vadde Ramu, et al.
Journal of the American Chemical Society (2020) Vol. 142, Iss. 23, pp. 10383-10399
Open Access | Times Cited: 64
Dichloroacetate Affects Mitochondrial Function and Stemness-Associated Properties in Pancreatic Cancer Cell Lines
Tiziana Tataranni, Francesca Agriesti, Consiglia Pacelli, et al.
Cells (2019) Vol. 8, Iss. 5, pp. 478-478
Open Access | Times Cited: 60
BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity
Houzong Yao, Shu Chen, Zhiqin Deng, et al.
Inorganic Chemistry (2020) Vol. 59, Iss. 16, pp. 11823-11833
Closed Access | Times Cited: 58
A Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt IV Complexes under Physiological Conditions
Alexander Kastner, Isabella Poetsch, Josef Mayr, et al.
Angewandte Chemie International Edition (2019) Vol. 58, Iss. 22, pp. 7464-7469
Open Access | Times Cited: 56
Pt(IV) Prodrugs with NSAIDs as Axial Ligands
Daniil Spector, Olga O. Krasnovskaya, Kirill G. Pavlov, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 3817-3817
Open Access | Times Cited: 49
Ketoprofen and Loxoprofen Platinum(IV) Complexes Displaying Antimetastatic Activities by Inducing DNA Damage, Inflammation Suppression, and Enhanced Immune Response
Zuojie Li, Qingpeng Wang, Linming Li, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 24, pp. 17920-17935
Closed Access | Times Cited: 48
Pt(iv) antitumor prodrugs: dogmas, paradigms, and realities
Mauro Ravera, Elisabetta Gabano, Michael J. McGlinchey, et al.
Dalton Transactions (2021) Vol. 51, Iss. 6, pp. 2121-2134
Closed Access | Times Cited: 46
Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?
Claudia Schmidt, Tomer Babu, Hana Kostrhunová, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 11364-11378
Closed Access | Times Cited: 43
Flavin-Conjugated Pt(IV) Anticancer Agents
Juan Sánchez-Camacho, Sonia Infante-Tadeo, Ana C. Carrasco, et al.
Inorganic Chemistry (2023) Vol. 62, Iss. 14, pp. 5644-5651
Open Access | Times Cited: 22
Platinum(IV) and platinum(II) anticancer complexes with biologically active releasable ligands
Pavel Štarha, Radka Křikavová
Coordination Chemistry Reviews (2023) Vol. 501, pp. 215578-215578
Closed Access | Times Cited: 22
Photoinduced Reduction of Novel Dual-Action Riboplatin Pt(IV) Prodrug
Olga O. Krasnovskaya, Roman Akasov, Daniil Spector, et al.
ACS Applied Materials & Interfaces (2023) Vol. 15, Iss. 10, pp. 12882-12894
Closed Access | Times Cited: 20
Page 1 - Next Page

Scroll to top